Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab vs Pembrolizumab in Nonsquamous NSCLC
NCT04750083Phase 3Unknown
- Sponsor
- Taizhou Hanzhong Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of pucotenlimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Taizhou Hanzhong Pharmaceuticals. Status: unknown.
02
Drugs
pucotenlimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT04750083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750083.